Oncology · Medical Literature
[News] First Nations cancer inequalities in Canada
Abstract
The expansion of colorectal cancer screening in Ontario, Canada, has coincided with new evidence showing that registered First Nations people experience higher colon cancer incidence at younger ages and poorer survival after breast, cervical, and colon cancer diagnoses than other residents.
Clinical relevance
Among registered First Nations people in Ontario, Canada, do cancer incidence, mortality, and post-diagnosis survival for breast, cervical, and colon cancers differ significantly from those of other Ontario residents, and do these disparities support changes to current screening age thresholds? __SNAPSHOT__ {"studyDesign":"Retrospective population-based cohort study (reported as a news article in The Lancet Oncology; primary study published in JAMA Network Open, July 10, 2026 [Sheppard AJ et al., JAMA Netw Open. 2026;9(7):e2622718])","setting":"Ontario, Canada; linked provincial health administrative databases (Indian Registry System, Registered Persons Database, Ontario Cancer Registry) at ICES (formerly Institute for Clinical Evaluative Sciences)","sampleSize":"Largest annual cohort included 146,498 First Nations people (median age 41 years [IQR 28–55]; 50.7% male) and 11,840,783 other Ontario residents (median age 48 years [IQR 33–62]; 51.1% female); data analyzed July 2020–March 2022","population":"Registered First Nations people identified via the Indian Registry System linked to the Registered Persons Database, compared with all other Ontario residents; incidence examined 1994–2018, mortality 1994–2017, survival 2007–2019","intervention":"Exposure: registered First Nations status in Ontario, Canada","comparator":"All other Ontario residents identified from the Registered Persons Database","primaryOutcome":"Cancer incidence (rate ratios), cancer mortality (rate ratios), and post-diagnosis survival (hazard ratios via Cox proportional hazards regression) for breast, cervical, and colon cancers; survival models adjusted for age, sex, comorbidity, and cancer stage at diagnosis","followUp":"Up to 25 years for incidence/mortality trends (1994–2018/2017); up to 12 years for survival analyses (2007–2019)","fundingSource":"Not reported in the Lancet Oncology news article; primary study conducted at ICES (government-affiliated research institute)"}
Key findings
Post-diagnosis survival was significantly worse for First Nations people across all three screening-program cancers compared with other Ontario residents after adjustment for age, sex, comorbidity, and cancer stage: breast cancer HR 1.51 (95% CI 1.28–1.76), cervical cancer HR 1.60 (95% CI 1.12–2.27), and colon cancer HR 1.19 (95% CI 1.07–1.32). In absolute terms, this represents a 51% higher risk of death after breast cancer diagnosis, a 60% higher risk after cervical cancer, and a 19% higher risk after colon cancer diagnosis compared with other Ontarians. Colon cancer incidence was elevated for First Nations people; crucially, those aged 40–49 years had a nearly identical elevated risk to those aged 50–74 years (incidence RR 1.27 [95% CI 1.06–1.51] and RR 1.29 [95% CI 1.20–1.40], respectively), supporting the clinical relevance of a younger screening onset age. First Nations people also had higher colon cancer mortality overall (RR 1.18 [95% CI 1.07–1.31]). Breast cancer was a notable exception for incidence and mortality: First Nations women had lower breast cancer incidence (RR 0.77 [95% CI 0.73–0.82]) and lower breast cancer mortality (RR 0.79 [95% CI 0.70–0.90]) compared with other Ontario women, yet paradoxically had worse post-diagnosis survival (HR 1.51), suggesting later stage at diagnosis or differential access to treatment. Cervical cancer incidence and mortality were higher in First Nations women overall (incidence RR 1.47 [95% CI 1.23–1.70]; mortality RR 2.26 [95% CI 1.78–2.88]), but both rates declined more rapidly over time among First Nations women than in the comparator group, representing the most encouraging trend in the dataset. NNT and NNH are not applicable to this observational study design and were not reported.
Practice implications
This large, population-level retrospective cohort study robustly establishes that registered First Nations people in Ontario experience significantly worse post-diagnosis survival across all three screening-program cancers — breast, cervical, and colon — even after adjustment for stage, comorbidity, age, and sex. This survival disparity cannot be attributed solely to later stage at diagnosis, as stage was accounted for in the models, implying that downstream inequities in treatment access, continuity of care, and culturally safe care are likely contributing factors that require further investigation. The finding that colon cancer risk among First Nations people aged 40–49 is statistically indistinguishable from the risk in the 50–74 age group directly informed Ontario's May 2026 policy decision to lower colorectal cancer screening eligibility from age 50 to 45 (and to 40 for those at increased risk). While trends over time showed some improvement — particularly the rapid decline in cervical cancer incidence and mortality in First Nations women — persistent survival disparities indicate that screening expansion alone is insufficient. The findings apply most directly to registered First Nations people in Ontario and may not fully represent Inuit, Métis, or urban unregistered Indigenous people, nor First Nations populations in other Canadian provinces, though the authors note relevance to Indigenous populations in comparable settler-colonial contexts (US, Australia, New Zealand). Clinicians should be aware that standard population screening age thresholds may underserve First Nations patients and that culturally safe care navigation and treatment continuity are priority unmet needs. Because only an abstract and secondary news reporting were available for the Lancet Oncology item at PMID N/A, this summary is based primarily on the primary JAMA Network Open publication (Sheppard AJ et al., 2026) and ICES institutional communications; clinicians should consult the full primary manuscript for complete methodological details. __LIMITATIONS__ 1. Observational design precludes causal inference; unmeasured confounders (e.g., socioeconomic status, geographic remoteness, health literacy, treatment type received) may not be fully captured in administrative data. 2. Identification of First Nations status relies on the Indian Registry System, which captures only registered (status) First Nations individuals — those not registered, Métis, Inuit, or off-reserve urban Indigenous people are excluded, likely underestimating the true scope of Indigenous cancer disparities in Ontario. 3. Cancer stage data availability was limited to the survival cohort period (2007–2019) and may be incomplete or variably recorded across institutions, particularly for remote or under-resourced communities. 4. The study does not capture care trajectory data after diagnosis (e.g., time to treatment, treatment completion, adherence), limiting the ability to identify the specific mechanisms driving survival disparities. 5. The cohort is geographically restricted to Ontario; generalizability to other provinces and territories with different Indigenous demographics, health system structures, and geography is uncertain. 6. Breast cancer paradox (lower incidence and mortality but worse post-diagnosis survival) may reflect incomplete stage ascertainment or selection bias in who reaches diagnosis in this population. 7. Data analyzed between July 2020 and March 2022; more recent trends, particularly the impact of COVID-19 disruptions on screening rates and cancer stage at diagnosis, are not captured. 8. Funding source was not reported in the Lancet Oncology news item, limiting assessment of potential conflicts of interest. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ Registered First Nations people in Ontario face significantly worse post-diagnosis survival across breast, cervical, and colon cancers — disparities that persist after adjustment for stage and comorbidity, implicating inequities in care delivery beyond screening access alone. The equivalence of colon cancer incidence risk between First Nations people aged 40–49 and 50–74 provided the evidentiary basis for Ontario's 2026 policy to lower colorectal cancer screening eligibility to age 45 (40 for increased risk), a directly practice-informing finding. Clinicians caring for First Nations patients should not rely solely on standard population screening thresholds, should actively facilitate earlier colorectal cancer screening, and should prioritize culturally safe care navigation and treatment continuity to address the documented post-diagnosis survival gap.